Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 1
1980 1
1982 2
1983 3
1984 1
1985 1
1986 6
1987 8
1988 4
1989 9
1990 8
1991 10
1992 6
1993 5
1994 14
1995 11
1996 14
1997 13
1998 13
1999 10
2000 9
2001 21
2002 22
2003 24
2004 16
2005 10
2006 24
2007 31
2008 26
2009 15
2010 20
2011 18
2012 23
2013 28
2014 30
2015 33
2016 29
2017 35
2018 28
2019 18
2020 16
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

564 results
Results by year
Filters applied: . Clear all
Page 1
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.
Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Pemmaraju N, et al. Among authors: duvic m. N Engl J Med. 2019 Apr 25;380(17):1628-1637. doi: 10.1056/NEJMoa1815105. N Engl J Med. 2019. PMID: 31018069 Clinical Trial.
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Kim YH, et al. Among authors: duvic m. Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Lancet Oncol. 2018. PMID: 30100375 Free article. Clinical Trial.
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group. Prince HM, et al. Among authors: duvic m. Lancet. 2017 Aug 5;390(10094):555-566. doi: 10.1016/S0140-6736(17)31266-7. Epub 2017 Jun 7. Lancet. 2017. PMID: 28600132
Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).
Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, Zackheim H, Duvic M, Estrach T, Lamberg S, Wood G, Dummer R, Ranki A, Burg G, Heald P, Pittelkow M, Bernengo MG, Sterry W, Laroche L, Trautinger F, Whittaker S; ISCL/EORTC. Olsen E, et al. Among authors: duvic m. Blood. 2007 Sep 15;110(6):1713-22. doi: 10.1182/blood-2007-03-055749. Epub 2007 May 31. Blood. 2007. PMID: 17540844 Free article. Review.
T-cell lymphoma secondary to checkpoint inhibitor therapy.
Anand K, Ensor J, Pingali SR, Hwu P, Duvic M, Chiang S, Miranda R, Zu Y, Iyer S. Anand K, et al. Among authors: duvic m. J Immunother Cancer. 2020 Feb;8(1):e000104. doi: 10.1136/jitc-2019-000104. J Immunother Cancer. 2020. PMID: 32114498 Free PMC article. Review.
United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic.
Zic JA, Ai W, Akilov OE, Carter JB, Duvic M, Foss F, Girardi M, Gru AA, Kim E, Musiek A, Olsen EA, Schieke SM, Shinohara M, Zain JM, Geskin LJ. Zic JA, et al. Among authors: duvic m. J Am Acad Dermatol. 2020 Aug;83(2):703-704. doi: 10.1016/j.jaad.2020.04.049. Epub 2020 Apr 16. J Am Acad Dermatol. 2020. PMID: 32305443 Free PMC article. No abstract available.
Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.
Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC; International Society for Cutaneous Lymphomas; United States Cutaneous Lymphoma Consortium; Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Olsen EA, et al. Among authors: duvic m. J Clin Oncol. 2011 Jun 20;29(18):2598-607. doi: 10.1200/JCO.2010.32.0630. Epub 2011 May 16. J Clin Oncol. 2011. PMID: 21576639 Free PMC article.
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy.
Curry JL, Tetzlaff MT, Nagarajan P, Drucker C, Diab A, Hymes SR, Duvic M, Hwu WJ, Wargo JA, Torres-Cabala CA, Rapini RP, Prieto VG. Curry JL, et al. Among authors: duvic m. J Cutan Pathol. 2017 Feb;44(2):158-176. doi: 10.1111/cup.12858. Epub 2016 Dec 21. J Cutan Pathol. 2017. PMID: 27859479 Review.
564 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page